Vistagen Therapeutics, Inc. · NASDAQ:VTGN
Vistagen Therapeutics — Investor Presentation (January 2018)
37 slides from Vistagen Therapeutics's investor presentation, Jan 8, 2018
Slide 1: Corporate Presentation January 2018
oy VistaGens ‘Therapeutics Corporate Presentation ~ JANUARY 2018 TON MEDICINE
Slide 2: Forward-looking Statements
Forward-looking Statements
Slide 3: VistaGen Overview
| VistaGen Overview NASDAQ: VIGN ) Depression market is large, Underserved and ready for new generation treatment options with fundamentally different MOAS G Short time line to two potentially major clinical catalysts in MDD {AV-101 is a new generation ‘oral antidepressant candidate in Phase 2 devel
Slide 4: Major Depressive Disorder (MDD)
remileogencom Major Depressive Disorder (MDD) SUBSTANTIAL MARKET WITH GROWING. VistaGen- UNMET NEED ‘in 10 in US, Over Age 12 OVER ‘Takes an Antidepressant? 300 MILLION PEOPLE WORLDWIDE — SUFFER FROM Slobal Depression Market 51456 DEPRESSION’ cae ese 2ore 2020 U.S. Drug- 73M 5.1M Girested NDB) 11.6M
Slide 5: AV-101 MDD Pipeline
eretagenson < 5 8 3 AV-101 MDD Pipeline on vaso wir rset sso sed Fit Sale get tert ae dee pas wae ay AV-101 (9-20) ceca ae Wen Ane carrera Treat MOD mama ce ean
Slide 6: Current MDD Drug Treatment Paradigm
eretagenson Current MDD Drug Treatment Paradigm VistaGen» SSRI/SNRI ‘SSRI/SNRI SSRI/SNRI £6 Weeks or more 4:6 Weeks or more 46 Weeks or more
Slide 7: Problems with Current Antidepressant Adjunctive Treatments
remileogencom PROBLEMS WITH CURRENT ANT ADJUN VE ATYPICAL ANTIPSYCHOTICS + Often do not work ital treatment effective in only 1 of 3 patients + Slow to work ~ May take 4 to 6 weeks or more to achieve antidepressant effects + Side-effects ~ Anxiety, decreased libido, nausea, seep, sisturbances, weigh
Slide 8: VistaGen's Target Drug Treatment Paradigm for MDD
VistaGen- VistaGen’s Target Drug Treatment Paradigm for MDD Temper ‘AV-101'S INITIAL FIT, AS AN ADJUNCTIVE THERAPY IN THE MDD TREATMENT ALGORITHM remileogencom il SSRI/SNRI SSRI/SNRI SSRI/SNRI 46 Weeks or more 4:6 Weeks or more 3.6 Weeks or more | | V1) |store! /// ive Atypical Antipsychotics in the
Slide 9: Ketamine breakthrough quote
VistaGen- remileogencom Recent data suggest that ketamine, given intravenously, might be the most important breakthrough in antidepressant treatment in decades.” Thomas Insel Former Director - US. National Institut of Mentol Health!
Slide 10: The Ketamine Story
The Ketamine Story —oe ‘A PARADIGM SHIFT TOWARDS NEW GENERATION ANTIDEPRESSANTS < e da FDA-approved Currenty, only Popular Club Drug: £ ‘anesthetic available by injection “Special K” + MOA is fundamentally different from all FDA-approved antidepressants and adjunctive atypical antipsychotics + Clini
Slide 11: NIMH Ketamine Study
remileogencom NIMH Ketamine Study BREAKTHROUGH ANTIDEPRESSANT E Responder" Rates at 1 Day with Ketamine in Treatment-Resistant MoD * Proportion of patients with treatment: resistant MDD with t east 50% Improvement in depression rating -FFECTS WITHIN 1 DAY OF A SINGLE TREAT ler Repose kein MENT sr re
Slide 12: Ketamine: New Hope for MDD Patients
zs VistaGens Ketamine 1 NEW HOPE FoR MDD PATIENTS. Ketamine For Severe Depression: "How Do You Not Offer This Drug To People?" = 7 ——— Drugs to Lift Depression in Hours Rather Than Weeks THE WALL STREET JOURNAL. a iT —— - TIME Cub Dros’ setarparovides Hope in Fight Against Depression
Slide 13: AV-101 (4-Chlorokynurenine)
i i AV-101 (4-Chlorokynurenine) "Trenpeice VistaGen: ‘A POTENTIAL BREAKTHROUGH ADJUNCTIVE TREATMENT FOR MAJOR DEPRESSIVE DISORDER ° © ORAL, NEW GENERATION ANTIDEPRESSANT CANDIDATE Rapidly absorbed through the gut, actively transported into the brain, Converted into its active metabolite (7-CI-KYNA),
Slide 14: AV-101 Mechanism of Action
remileogencom AV-101 (4-Chlorokynurenine) Mechanism of Action AV-101'S METABOLITE (7-CI-KYNA) INHIBITS NMDA RECEPTOR ACTIVITY NMDAReceptor Pharmacology (=m GREETS "0 i
Slide 15: AV-101 vs. Ketamine
AV-101 vs. Ketamine PRECLINICAL EVIDENCE OF KETAMINE-UKE ANTIDEPRESSANT EFFECTS WITHOUT KETAMINE-LIKE SAFETY CONCERNS. S The Journal of Pharmacology and Experimental Theropeutics, “The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/Glycine,-Site
Slide 16: NIH Support for AV-101
NIH Support for AV-101 VALUABLE LONG-TERM RELATION irect funding for AV-101 Preclinical and Phase 1 ISHIP AND SUPPORT FOR AV-101 Di VELOPMENT Clinical and financial support for AV-101 Phase 2 $8.8 milion in direct non-dilutive cash awards for ‘support of AV-101 preclinical development and first-in-h
Slide 17: NIH-Sponsored AV-101 Phase 1 Safety Studies
{ i Ke i NIH-Sponsored AV-101 Phase 1 Safety Studies Trerpautcs NO KETAMINE-LIKE SAFETY CONCERNS AV-101 Phase 1a Study ‘AV-101 Phase 1b Study + Randomized, double-blind, placebo controled + Randomized, double-blind placebo-contoled + Single or dose with sequent dose-sclation + Multiple ora dose (ay
Slide 18: NIMH-Sponsored AV-101 Phase 2 Monotherapy Study
| NIMH-Sponsored AV-101 Phase 2 Monotherapy Study MDD ORAL MONOTHERAPY Principal Investigator: Dr. Carlos Zarate, Jr, NIMH + Single site: NIMH * Double-blind, placebo- controlled, crossover design + Single oral dose ‘monotherapy, in treatment resistant MDD patients, ‘once per day for 14 days + Targe
Slide 19: AV-101 Phase 2 Adjunctive Treatment Study
Ie | AV-101 Phase 2 Adjunctive Treatment Study Treneis NEW GENERATION ORAL ADJUNCTIVE TREATMENT FOR INADEQUATE SSRI/SNRI MONOTHERAPY Principal Investigatos Primary Endpoint coun Dr. Maurizio Fava, Harvard University Ethcacy demorstated bya decease soniarendins + Projected enroliment: ~180 patients +
Slide 20: Short Time Horizon to Potential Clinical Catalysts
i le i Vista . < ec nigeane en. i Short Time Horizon to Potential Clinical Catalysts "Tremp. 2H ] yaw jm FOA green light fr Launch AV-101 AV-101 Phase 2 AV=i01 Phase 2 Phase 2 MOD MOD adjunctive MOD adjunctive adjunctive teeatment study treatment sy ‘rentment study topine eults ¥ Completed 1H Potent
Slide 21: Potential in MDD and Additional CNS Markets
| Potential in MDD and Additional CNS Markets INDICATION | PRODUCT AV-101 has potential in multiple CNS markets Neurodegenerative Neuropsychiatric ‘ VistaGen» ‘OPPORTUNITY Demonstrated ketamine-like efficacy in animal models. for depression; safe, well tolerated in Phase 1 studies; ‘currently in NIH
Slide 22: Preeminent CNS Clinical and Regulatory Advisors
remileogencom HARVARD. Preeminent CNS Clinical and Regulatory Advisors Dyscuniensiy VistaGen» Maurizio Fava, M.D. Professor of Psychiatry Harvard Media! Schoo! rector, Divison of Clncal Research Massachusetts General Hospital (MGH) Research insti Executive Orector, MGH Cline Trials Network and istit
Slide 23: Experienced Team Leading Execution
| Experienced Team Leading Execution Shawn K. Singh Chief Executive Officer Ralph Snodgrass, Ph.D. President, Chief Scientific Officer 2a yeas of experience in senior biotechnology ‘management + Progenitor Uneberger Comprehensive Cancer Center ‘Mork A. Smith, M.D, PRO. Chief Medical Officer 2 yes of
Slide 24: Highlights
Spee , : ee Highlights
Slide 25: Company Contact
© Company Contact: Marka MePartland VistaGen Therapeutics nc. Phone: » 1 (650) $77-3606 eaeevencenen Ww vistagen,com. DEVELOPING NEW GENERATION MEDICINES FOR DEPRESSION AND OTHER CNS DISORDERS
Slide 26: Supplemental Information
Supplemental Information
Slide 27: Board of Directors
Board of Directors remileogencom Jerry Gin, Ph.0,, MBA Director 45 years of healthcare industry experience Co Founder of Ocuex (acquired by Allergan for $230M) Serves as Co-Founder, President and CEO of ‘Shawn Singh CEO, Director 25 years of experience wth biopharmaceutial companies, a venture <apta
Slide 28: AV-101's Mechanism of Action
i AV-101's Mechanism of Action Ke. VistaGen-
Slide 29: AV-101 Advantages vs. NR2B Specific NMDA Receptor Antagonists
eretagenson VistaGen» AV-101 Advantages vs. NR2B Specific Trerpautcs NMDA RECEPTOR ANTAGONISTS ‘There are 9 different variants of the NMDAR Dicheteromeric NMDARs Tri-heteromeric NMDARS VA W816 20 YAR ARB RARE 1728720 28K o0000 OH080 Mt Gpruonrepermigeninmin ss + es s+ + Inaddition to neuronal cell-s
Slide 30: AV-101 vs. Ketamine in Published Preclinical Studies
remileogencom AV-101 vs. Ketamine in Published Preclinical Studies Benefits ‘av-101 Ketamine Forced-swim Tal-suspension Leamed:-hlplessness Ua Novelty-suppressed feeding uncer Negative Behavioral Effects __AV-101 Ketamine ‘Abusive potenti Ne Yes No Yes No ves No Yes Ne ves VistaGen»
Slide 31: AV-101 and Ketamine: Similar Efficacy in Preclinical Studies
remileogencom AV-101 and Ketamine VistaGen- SIMILAR EFFICACY IN PUBLISHED PRECLINICAL STUDIES A single dose of AV-101 demonstrated acute (24 h) NBQX (AMPA antagonist) blocks AV-101 effects and chronic (7 d) antidepressant effects similar to which supports AMPA receptor activation as. ketamine necess
Slide 32: AV-101 Had No Negative Behavioral Effects of Ketamine
remileogencom AV-101 Had No Negative Behavioral Effects of Ketamine _ in Published Preclinical Studies Hyper-movement Circling | i ssa I VistaGen- "Terpecs
Slide 33: AV-101 for Parkinson's Disease Levodopa-Induced Dyskinesia
remileogencom AV-101 for Parkinson's disease levodopa-induced ‘Trerpeutcs dyskinesia (PD LID) uNMeT MEDICAL NEED RATIONALE EVIDENCE FoR Av-101 = NEXT STEP. ‘Levodopa is the most fHective teatment for kinson's disease (PD), i levodopa therapy is typically reserved for Cross-over study of AV-101 vs pl
Slide 34: AV-101 for Neuropathic Pain
AV-101 for Neuropathic Pain ‘Taromtcs : b) MEDICAL NEED RATIONALE EVIDENCE FOR AV-101 NEXT STEP population suffers from NMDA receptor AV-101 reduced re severe neuropathic pain antagonists such as ‘neuropathic pain in arta: addictive opioids or ‘neuropathic pain but with similar eficacy to placebo in
Slide 35: VistaStem: Cardiac Stem Cell Technology
VistaStem Maes CARDIAC STEM CELL TECHNOLOGY FOR REGENERATIVE MEDICINE AND DRUG RESCUE “Bayer Teams Up With Versant Ventures to ‘THE WALLSTREET JOURNAL Develop Stem-Cell Therapies” December 2017 + Key participant in FOA's Comprehensive in vitro Proarthythmia Assay (CiPA) initiative focused on next ‘g
Slide 36: Regenerative Medicine Opportunities
Ke) . - a5 VistaGen. Regenerative Medicine Opportunities ‘ener remileogencom Hematopoiesis (Blood) Cardiovascular disease disease + Cardiac infarction + Cancer therapies + Coronary heart disease + Bone marrow replacement + Immune enhancement Cell-based Liver disease Therapeutic + Acute liver failure
Slide 37: Publications
Publications
VistaGen Therapeutics — Investor Presentation (January 2018) on 6ix